Patents Assigned to Lohocla Research Corporation
-
Patent number: 11130737Abstract: Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I): in which the substituents thereof are defined as set forth in the specification.Type: GrantFiled: October 7, 2019Date of Patent: September 28, 2021Assignee: LOHOCLA RESEARCH CORPORATIONInventor: Boris Tabakoff
-
Patent number: 10875831Abstract: A method for preparing an alkyl 5,7-dihalo-1,4-dihydro-4-oxoquinoline-2-carboxylate ester is described herein. The method comprises cyclizing a compound of Formula III with Eaton's reagent in heated continuous flow reactor to form a compound of Formula IV wherein in Formula III and Formula IV, each X independently is a halogen atom; and each R independently is C1 to C4 alkyl. Optionally, a cosolvent such as dichloromethane can be included with the Eaton's reagent. A method of preparing a diphenylureido-dihalokynurenic acid alkyl ester of Formula VI from the compound of Formula IV also is described.Type: GrantFiled: August 12, 2019Date of Patent: December 29, 2020Assignee: Lohocla Research CorporationInventors: Sergiy Krasutsky, Scott Tweedie, Gurusankar Ramamoorthy
-
Patent number: 10435371Abstract: Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I): in which the substituents thereof are defined as set forth in the specification.Type: GrantFiled: September 13, 2018Date of Patent: October 8, 2019Assignee: LOHOCLA RESEARCH CORPORATIONInventor: Boris Tabakoff
-
Patent number: 10391088Abstract: Analgesic compositions comprise an aminoquinoline together with an opioid, a non-steroidal anti-inflammatory drug (NSAID), a NE/5-HT reuptake inhibitor, or a combination thereof. The aminoquinoline potentiates bioactivity of opioids, NSAIDs and NE/5-HT reuptake inhibitors.Type: GrantFiled: September 7, 2018Date of Patent: August 27, 2019Assignee: Lohocla Research CorporationInventor: Boris Tabakoff
-
Patent number: 10112905Abstract: Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I) which is defined in the specification.Type: GrantFiled: June 18, 2015Date of Patent: October 30, 2018Assignee: LOHOCLA RESEARCH CORPORATIONInventor: Boris Tabakoff
-
Patent number: 8168402Abstract: The present invention relates to compositions and methods for identifying and quantifying platelet proteins that relate to various bodily states. The present invention further provides methods and compositions for determining whether an individual is using alcohol or other licit or illicit drugs at levels hazardous or harmful to their health. The invention also provides methods for identifying individuals who would benefit from or who may be harmed by specific medications or therapies.Type: GrantFiled: November 3, 2006Date of Patent: May 1, 2012Assignee: Lohocla Research CorporationInventors: Boris Tabakoff, Lawrence Snell
-
Publication number: 20110184018Abstract: A method for the treatment of peripheral neuropathic pain in a mammal is provided. The method comprises administering to a mammal (e.g., a human) suffering from peripheral neuropathic pain a pain relieving amount of a diarylureido-dihalokynurenate compound. Preferred diarylureido-dihalokynurenate compounds are esters (e.g., ethyl esters). Particularly preferred are diphenylureido-dichlorokynurenate compounds. The diphenylureido-dihalokynurenate compounds are shown to be agonists of cannabinoid receptor 1 (CB1) and stimulate CB1 activity.Type: ApplicationFiled: April 7, 2011Publication date: July 28, 2011Applicant: LOHOCLA RESEARCH CORPORATIONInventor: Boris TABAKOFF
-
Patent number: 7923458Abstract: A method for the treatment of chronic pain in a mammal is provided. The method comprises administering to a mammal (e.g., a human) suffering from chronic pain a pain relieving amount of a diarylureido-dihalokynurenate compound. Preferred diarylureido-dihalokynurenate compounds are esters (e.g., ethyl esters). Particularly preferred are diphenylureido-dichlorokynurenate compounds.Type: GrantFiled: October 6, 2006Date of Patent: April 12, 2011Assignee: Lohocla Research CorporationInventor: Boris Tabakoff
-
Publication number: 20090305318Abstract: The present invention relates to compositions and methods for identifying and quantifying platelet proteins. As certain behaviors and medical conditions alter the quantity of various platelet membrane proteins, the tools of the present invention are suitable for identification of biomarkers of these bodily states. For instance, the present invention provides methods and compositions for determining whether an individual is using alcohol or other licit or illicit drugs at levels hazardous or harmful to their health. The invention also provides methods for identifying individuals who would benefit from or who may be harmed by specific medications or therapies.Type: ApplicationFiled: November 3, 2006Publication date: December 10, 2009Applicant: Lohocla Research CorporationInventors: Boris Tabakoff, Lawrence Snell
-
Patent number: 6962930Abstract: Compounds, composition and method for ameliorating alcohol or drug dependency withdrawal syndromes and withdrawal-induced brain damage are disclosed. In particular, a series of N-substituted-4-uredo-5,7-dihalo-2-carboxy quinoline compounds are disclosed having combined properties as antagonists of voltage-sensitive sodium channels (VSNaC) and as selective competitive antagonists at the strychnine-intensive glycine site of N-methyl-D-aspartate (NMDA) receptors. The disclosed compounds prevent or reduce the signs and symptoms of neurohyperexcitability and particularly the neurohyperexcitability associated with withdrawal syndrome manifested by patients upon withdrawal from chronic use of dependence inducing agents (e.g. ethanol, barbiturates, opiates etc.).Type: GrantFiled: June 5, 1998Date of Patent: November 8, 2005Assignee: Lohocla Research CorporationInventors: Boris Tabakoff, Lawrence Snell, Paula L. Hoffman